Patrick Reimann, Verena Petzer, Axel Mündlein, Bernd Hartmann, Luciano Severgnini, Alex Winkler, Theresia Lang, Minh Huynh, Klaus Gasser, Julia Rüger, Michele Atzl, Sylvia Mink, Peter Fraunberger, Stefan Schmidt, Normann Steiner, Andrea Griesmacher, Eberhard Gunsilius, David Nachbaur, Wolfgang Willenbacher, Dominik Wolf, Thomas Winder, Magdalena Anna Benda
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in hematological patients under real-life conditions. Tixagevimab/cilgavimab was administered to 155 hematological patients (March-August 2022) at two Austrian centres. S/RBD-antibody assessments were performed before (T0), four weeks (T1), and six months (T2) after application...
March 2, 2024: Annals of Hematology